Omthera Pharmaceuticals, Inc. 4
4 · Omthera Pharmaceuticals, Inc. · Filed Jul 18, 2013
Insider Transaction Report
Form 4
MOTT DAVID M
Director10% Owner
Transactions
- Disposition to Issuer
Common Stock
2013-07-18−5,833,213→ 0 total(indirect: See Note 2)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger by and among the Company, Zeneca, Inc. and KAFA Acquisition Corp., dated May 27, 2013, each share of the Company's common stock was exchanged for $12.70 in cash, without interest, less any applicable withholding taxes, plus one contractual contingent value right, which represents the right to receive contingent payments of up to approximately $4.70 in cash in the aggregate, without interest, less any applicable withholding taxes, if specified milestones are achieved within agreed upon time periods.
- [F2]The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of NEA 13, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the securities held by NEA 13, except to the extent of his pecuniary interest therein.